Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PureTech Turns To Its Wholly Owned Pipeline Amid 2021 Loss

Executive Summary

The US biotech saw a net loss last year despite increased sales and has decided to focus more on its wholly owned pipeline, which includes a safer formulation of a Roche pulmonary fibrosis product.

You may also be interested in...



Gelesis Presents Data Showing GS200, The Device That Looks Like A Drug, Treats Obesity

Results of the LIGHT UP study, which included prediabetic and diabetic subjects, could support FDA approval of GS200.

PureTech Takes On Roche With Improved IPF Drug

The firm’s lead candidate has shown strong tolerability in an early-stage trial for idiopathic pulmonary fibrosis, sparking hopes for registration-enabling studies and a streamlined development plan.

Ariceum Hopes To One-Up Novartis Drug With Potent Radiopharmaceutical Focus

Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel